Health Care [ 9/12 ] | Pharmaceuticals [ 38/74 ]
NASDAQ | Common Stock
Tvardi Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of novel, oral, and small molecule therapies targeting STAT3 to treat fibrosis-driven diseases with significant unmet need in the United States.
The company's lead product candidates include TTI-101, which is in Phase 2 clinical development stage for fibrosis-driven diseases with an initial focus on idiopathic pulmonary fibrosis (IPF), and hepatocellular carcinoma (HCC); and TTI-109, an oral, small molecule STAT3 inhibitor which is in pre-clinical stage.
Tvardi Therapeutics, Inc. was founded in 2017 and is based in Sugar Land, Texas.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Nov 13, 25 | -0.59 Increased by +92.80% | -0.81 Increased by +27.16% |
| Aug 14, 25 | 0.51 Increased by +288.89% | -0.39 Increased by +230.77% |
| May 13, 25 | -0.50 Increased by +10.71% | -0.58 Increased by +13.79% |
| Feb 26, 25 | -5.21 Decreased by -783.05% | -0.20 Decreased by -2.55 K% |
| Nov 29, 24 | -8.19 Decreased by -1.47 K% | -0.24 Decreased by -3.31 K% |
| Aug 5, 24 | -0.27 Increased by +53.45% | -0.26 Decreased by -3.85% |
| May 13, 24 | -0.56 Decreased by -14.29% | -0.40 Decreased by -40.00% |
| Mar 4, 24 | -0.59 Decreased by -5.36% | -0.45 Decreased by -31.11% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Sep 30, 25 | 0.00 Decreased by -100.00% | -5.53 M Increased by +55.70% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 25 | 0.00 Decreased by -100.00% | 4.17 M Increased by +159.74% | Increased by +N/A% Increased by +N/A% |
| Mar 31, 25 | 2.57 M Increased by +20.33% | -4.91 M Increased by +84.02% | Decreased by -190.97% Increased by +86.72% |
| Dec 31, 24 | 1.46 M Decreased by -51.56% | -7.68 M Increased by +76.25% | Decreased by -527.77% Increased by +50.97% |
| Sep 30, 24 | 2.56 M Decreased by -47.47% | -12.48 M Increased by +55.49% | Decreased by -488.11% Increased by +15.27% |
| Jun 30, 24 | 991.00 K - | -6.97 M - | Decreased by -703.83% - |
| Mar 31, 24 | 2.13 M - | -30.70 M - | Decreased by -1.44 K% - |
| Dec 31, 23 | 3.00 M - | -32.34 M - | Decreased by -1.08 K% - |